<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893227</url>
  </required_header>
  <id_info>
    <org_study_id>S62213</org_study_id>
    <nct_id>NCT03893227</nct_id>
  </id_info>
  <brief_title>Prevalence of Nasal Hyperreactivity in Chronic Upper Airway Inflammation</brief_title>
  <official_title>Prevalence of Nasal Hyperreactivity in Chronic Upper Airway Inflammation: a Prevalence Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rhinitis, or inflammation of the nasal mucosa, can present with nasal obstruction, nasal
      discharge, itch or sneezing. If the sinusal mucosa is involved as well, it is called
      rhinosinusitis and facial pain or loss of smell is possible. Several causes are known, such
      as an underlying allergy (&quot;allergic rhinitis&quot;, AR). If at least 2 symptoms are present for at
      least 12 weeks, it is called &quot;chronic rhinosinusitis&quot; (CRS).

      Up to 2/3 of the AR and CRS patients have symptoms upon exposure to triggers such as sudden
      temperature changes, smoke, fragrancesâ€¦ a phenomenon called &quot;nasal hyperreactivity&quot; (NHR). It
      is currently not clear why some patients suffer NHR while others do not.

      In this study, the investigators want to determine the prevalence and severity of nasal
      hyperreactivity in patients with chronic upper airway inflammation. To this end, patients and
      healthy controls will be asked to fill out a questionnaire inquiring presence and severity of
      nasal symptoms upon exposure to particular environmental triggers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the proportion of patients and healthy volunteers with nasal hyperreactivity</measure>
    <time_frame>3 months</time_frame>
    <description>Every participant will fill out a questionnaire inquiring presence of nasal symptoms evoked by environmental triggers and lasting longer than ten minutes (nasal hyperreactivity). The proportion of patients and healthy volunteers with nasal hyperreactivity will be compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of nasal symptom severity in patients and healthy volunteers with and without nasal hyperreactivity.</measure>
    <time_frame>3 months</time_frame>
    <description>Every participant will fill out a questionnaire inquiring nasal symptom severity by means of a visual analogue scale (VAS). The severity of symptoms will be scored on a horizontal line of 10 cm, where 0 cm equals &quot;no symptoms&quot; and 10 cm equals &quot;very severe symptoms&quot;. The VAS-scores of patients and healthy volunteers with and without nasal hyperreactivity will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the proportion of healthy volunteers and four groups of patients (allergic rhinitis, non-allergic non-infectious rhinitis, chronic rhinosinusitis with nasal polyps, chronic rhinosinusitis without nasal polyps) with nasal hyperreactivity.</measure>
    <time_frame>3 months</time_frame>
    <description>Every participant will fill out a questionnaire inquiring presence of nasal symptoms evoked by environmental triggers and lasting longer than ten minutes (nasal hyperreactivity). The proportion of healthy volunteers and four groups of patients (allergic rhinitis, non-allergic non-infectious rhinitis, chronic rhinosinusitis with nasal polyps, chronic rhinosinusitis without nasal polyps) with nasal hyperreactivity will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of nasal symptom severity in healthy volunteers and four groups of patients [allergic rhinitis, non-allergic non-infectious rhinitis, chronic rhinosinusitis (CRS) with and CRS without nasal polyps] with and without nasal hyperreactivity.</measure>
    <time_frame>3 months</time_frame>
    <description>Every participant will fill out a questionnaire inquiring nasal symptom severity by means of a visual analogue scale (VAS). The severity of symptoms will be scored on a horizontal line of 10 cm, where 0 cm equals &quot;no symptoms&quot; and 10 cm equals &quot;very severe symptoms&quot;. The VAS-scores of healthy volunteers and four groups of patients (allergic rhinitis, non-allergic non-infectious rhinitis, chronic rhinosinusitis with nasal polyps, chronic rhinosinusitis without nasal polyps) with and without nasal hyperreactivity will be compared.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Hyperactivity</condition>
  <condition>Chronic Rhinosinusitis (Diagnosis)</condition>
  <condition>Chronic Rhinitis</condition>
  <condition>Upper Respiratory Disease</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients with chronic upper airway inflammation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <description>Healthy controls without chronic upper airway inflammation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Patients and healthy controls will fill out a questionnaire</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic inflammation of the upper airways. Controls without chronic
        inflammation of the upper airways.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        PATIENTS

        Inclusion Criteria:

          -  age 18-65 y

          -  Nasal inflammatory symptoms for 12 weeks or longer (nasal obstruction, post-nasal
             drip, rhinorrhea, loss of smell, sneezing/itch, facial pain)

          -  Signed informed consent

        Exclusion Criteria:

        - Current or medical history of malignancy in the last ten years

        CONTROLS

        Inclusion Criteria:

          -  age 18-65 y

          -  No nasal inflammatory symptoms for 12 weeks or longer (nasal obstruction, post-nasal
             drip, rhinorrhea, loss of smell, sneezing/itch, facial pain)

          -  Signed informed consent

        Exclusion Criteria:

        - Current or medical history of malignancy in the last ten years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Van Gerven, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wout Backaert, MD</last_name>
    <phone>+3216346165</phone>
    <email>wout.backaert@kuleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leen Cools, MSc</last_name>
    <phone>+3216342037</phone>
    <email>leen.cools@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZLeuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wout Backaert, MD</last_name>
      <phone>+3216346165</phone>
      <email>wout.backaert@kuleuven.be</email>
    </contact>
    <investigator>
      <last_name>Laura Van Gerven, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>March 27, 2019</last_update_submitted>
  <last_update_submitted_qc>March 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Laura Van Gerven</investigator_full_name>
    <investigator_title>Professor doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

